These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23918069)

  • 21. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
    Lee N; Lee JL; Lee JY
    Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.
    Steegmann JL; Baccarani M; Breccia M; Casado LF; García-Gutiérrez V; Hochhaus A; Kim DW; Kim TD; Khoury HJ; Le Coutre P; Mayer J; Milojkovic D; Porkka K; Rea D; Rosti G; Saussele S; Hehlmann R; Clark RE
    Leukemia; 2016 Aug; 30(8):1648-71. PubMed ID: 27121688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
    Chiwata M; Itonaga H; Sato S; Hashimoto M; Fujioka M; Kasai S; Sakamoto H; Toriyama E; Nakashima J; Kamijo R; Kitanosono H; Kobayashi Y; Horai M; Taguchi M; Matsuo M; Makiyama J; Takasaki Y; Matsuo E; Horio K; Ando K; Sawayama Y; Taguchi J; Kawaguchi Y; Tsushima H; Imanishi D; Imaizumi Y; Yoshida S; Jo T; Nonaka H; Moriuchi Y; Nagai K; Yokota KI; Hata T; Miyazaki Y
    Intern Med; 2021 Jul; 60(14):2207-2216. PubMed ID: 33612681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
    Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
    Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.
    Biswas B; Ghadyalpatil N; Krishna MV; Deshmukh J
    Indian J Cancer; 2017 Dec; 54(Supplement):S55-S64. PubMed ID: 29292709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors.
    Sayegh N; Yirerong J; Agarwal N; Addison D; Fradley M; Cortes J; Weintraub NL; Sayed N; Raval G; Guha A
    Curr Cardiol Rep; 2023 Apr; 25(4):269-280. PubMed ID: 36795308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.
    Bardaro F; Stirpe E
    J Oncol Pharm Pract; 2022 Jun; 28(4):989-994. PubMed ID: 35037771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.
    Shyam Sunder S; Sharma UC; Pokharel S
    Signal Transduct Target Ther; 2023 Jul; 8(1):262. PubMed ID: 37414756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
    Srikanthan A; Ethier JL; Ocana A; Seruga B; Krzyzanowska MK; Amir E
    PLoS One; 2015; 10(3):e0122735. PubMed ID: 25815472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of target small molecule tyrosine kinase inhibitors that need monitoring and clinical application of protocol for early detection of cancer therapeutics-related cardiac dysfunction using signal detection: An investigation of real world data.
    Mizuno T; Sakai T; Tanabe K; Kozaki K; Umemura T; Higashikawa M; Kimura T; Yamada T; Goto N; Ohtsu F
    J Oncol Pharm Pract; 2021 Jun; 27(4):804-814. PubMed ID: 32539664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.
    Schiefer M; Hendriks LEL; Dinh T; Lalji U; Dingemans AC
    Eur J Cancer; 2018 Mar; 91():92-98. PubMed ID: 29413968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
    Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
    Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors.
    Nakamae M; Nakamae H; Hashimoto M; Koh H; Nakashima Y; Hirose A; Hino M
    Int J Hematol; 2022 Mar; 115(3):329-335. PubMed ID: 34787835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.
    Awan FT; Addison D; Alfraih F; Baratta SJ; Campos RN; Cugliari MS; Goh YT; Ionin VA; Mundnich S; Sverdlov AL; Tam C; Ysebaert L
    Blood Adv; 2022 Sep; 6(18):5516-5525. PubMed ID: 35790105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.
    Chitturi KR; Burns EA; Muhsen IN; Anand K; Trachtenberg BH
    Curr Oncol Rep; 2022 Apr; 24(4):475-491. PubMed ID: 35192115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment.
    Budolfsen C; Faber J; Grimm D; Krüger M; Bauer J; Wehland M; Infanger M; Magnusson NE
    Curr Vasc Pharmacol; 2019; 17(6):618-634. PubMed ID: 30706818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tirosine kinase inhibitors adverse events.
    Campiotti L; Maresca A; Guasti L; Grandi AM
    Oncologist; 2014 Mar; 19(3):306-7. PubMed ID: 24643716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.